Insider Selling: Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Insider Sells 1,078,600 Shares of Stock

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) insider Neal Flomenberg sold 1,078,600 shares of the company’s stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the sale, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Tevogen Bio Stock Performance

TVGN stock opened at $1.80 on Tuesday. The company’s 50 day moving average price is $0.58 and its 200 day moving average price is $0.85. Tevogen Bio Holdings Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $21.09.

Wall Street Analysts Forecast Growth

Separately, Fundamental Research set a $4.20 price target on Tevogen Bio and gave the stock a “buy” rating in a report on Friday, June 28th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC acquired a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio comprises approximately 3.0% of Portland Global Advisors LLC’s investment portfolio, making the stock its 9th largest position. Portland Global Advisors LLC owned about 36.55% of Tevogen Bio at the end of the most recent reporting period.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.